WebAug 4, 2024 · The system is intended for use in standalone surgery for patients with primary open-angle glaucoma whose increased intraocular pressure (IOP) is uncontrolled by … WebJan 14, 2024 · Alcon plans to pursue standalone surgery indications for Hydrus Microstent in the United States with clinical trials underway. Glaukos Corp. received 510 (k) clearance from the FDA for the iPRIME Viscodelivery System, a sterile, single-use, minimally invasive device for the delivery of viscoelastic fluid during ophthalmic surgery.
The Daily Biotech Pulse: Glaukos Gets FDA Nod,…
WebAccessGUDID - iPRIME (00853704002456)- Viscodelivery System. Brand Name: iPRIME Version or Model: VCP100 Commercial Distribution Status: In Commercial Distribution … WebThe company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. flint burnaby
MAUDE - Manufacturer and User Facility Device Experience
WebJan 6, 2024 · Glaukos (NYSE: GKOS) receives 510 (k) clearance from the FDA for its iPRIME viscodelivery system. It is a single-use, minimally-invasive device for the delivery of … WebJan 10, 2024 · Viscoelastic System Approved Glaukos recently announced that it has received 510 (k) clearance from the U.S. Food and Drug Administration for the iPRIME Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. Read more. Back to Top WebJan 7, 2024 · Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name Rencofilstat Hepion ... flint builders sacramento